cardiomyopathy
Within        6 months of zafirlukast being made available on the market, 8 patients who       received the agent for moderate to severe asthma developed eosinophilia,       pulmonary infiltrates, cardiomyopathy and other signs of vasculitis; the syndrome       that these patients developed was characteristic of the Churg-Strauss syndrome.
Within        6 months of zafirlukast being made available on the market, 8  @OBJECT$  who       received the agent for moderate to severe asthma  @PREDICAT$  eosinophilia,       pulmonary infiltrates,  @SUBJECT$  and other signs of vasculitis; the syndrome       that these patients developed was characteristic of the Churg-Strauss syndrome.